Boston, MA -- (SBWIRE) -- 02/17/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Get More Details on this Report and a Full Table of Contents at Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

Companies Mentioned in this Report: 3-V Biosciences Inc, 3SBio Inc, 4SC AG, AbbVie Inc, Ability Pharmaceuticals SL, ACEA Biosciences Inc, Acetylon Pharmaceuticals Inc, Adamed Sp z oo, Adaptimmune Therapeutics Plc, Advanced Cancer Therapeutics, Advantagene Inc, Advenchen Laboratories LLC, Allist Shanghai Pharmaceutical Technology Co Ltd, Almac Discovery Ltd, Altimmune Inc, Altor BioScience Corp, Amgen Inc, Andarix Pharmaceuticals Inc, AndroScience Corp, Apac Biotech Pvt Ltd, APO-T BV, Aptevo Therapeutics Inc, Aptose Biosciences Inc, Argos Therapeutics Inc, Ariad Pharmaceuticals Inc, ARMO Biosciences Inc, Arog Pharmaceuticals Inc, ArQule Inc, Array BioPharma Inc, Arrien Pharmaceuticals LLC, Asana BioSciences LLC, Astellas Pharma Inc, Asterias Biotherapeutics Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, ATLAB Pharma SAS, Atreca Inc, Aurigene Discovery Technologies Ltd, AVEO Pharmaceuticals Inc, Axelar AB, Azaya Therapeutics Inc, Basilea Pharmaceutica Ltd, Batu Biologics Inc, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, BerGenBio AS, Beta Pharma Inc, Betta Pharmaceuticals Co Ltd, BeyondSpring Pharmaceuticals Inc, Bio-Path Holdings Inc, Biocad, BioCancell Ltd, Biocon Ltd, BioLineRx Ltd, Bionovis SA, Biothera Pharmaceutical Inc, Blueprint Medicines Corp, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences Inc, CanBas Co Ltd, Cantargia AB, CASI Pharmaceuticals Inc, CBT Pharmaceuticals Inc, Celgene Corp, CellAct Pharma GmbH, Cellceutix Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Cellmid Ltd, Cellular Biomedicine Group Inc, Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co Ltd, Cielo Therapeutics Inc, Cipla Ltd, Cleave Biosciences Inc, Coherus BioSciences Inc, Corcept Therapeutics Inc, Cornerstone Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, Critical Outcome Technologies Inc, CSPC Pharmaceutical Group Limited, CTI BioPharma Corp, CytImmune Sciences Inc, CytomX Therapeutics Inc, CytRx Corp, Daiichi Sankyo Company Ltd, DanDrit Biotech A/S, DEKK-TEC Inc, DelMar Pharmaceuticals Inc, Denovo Biopharma LLC, DiNonA Inc, Domainex Ltd, DormaTarg Inc, Double Bond Pharmaceutical International AB, Dr. Reddy's Laboratories Ltd, Eagle Pharmaceuticals Inc, EirGenix Inc, Eisai Co Ltd, Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endocyte Inc, EnGeneIC Ltd, EntreChem SL, Enumeral Biomedical Holdings Inc, Eudendron Srl, Evotec AG, Exelixis Inc, F. Hoffmann-La Roche Ltd, FibroStatin SL, Five Prime Therapeutics Inc, Fujifilm Corp, G&E Herbal Biotechnology Co Ltd, Ganymed Pharmaceuticals AG, Gene Techno Science Co Ltd, Genelux Corp, Genentech Inc, Genmab A/S, Genocea Biosciences Inc, Genor BioPharma Co Ltd, Genosco Inc, Genzyme Corp, Gilead Sciences Inc, GlaxoSmithKline Plc, Globeimmune Inc, GlycaNova Norway AS, Glycotope GmbH, Golden Biotechnology Corp, Gradalis Inc, Grunenthal GmbH, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Heat Biologics Inc, HEC Pharm Co Ltd, Helix BioPharma Corp, Hemispherx Biopharma Inc, Heptares Therapeutics Ltd, HitGen LTD, Horizon Pharma Plc, Hutchison MediPharma Ltd, iCeutica Inc, Ideaya Biosciences Inc, Ignyta Inc, Immune Design Corp, Immune Pharmaceuticals Inc, ImmunGene Inc, Immunocore Ltd, ImmunoGen Inc, Immunome Inc, Immunomedics Inc, Incuron LLC, Incyte Corp, Infinity Pharmaceuticals Inc, Inflection Biosciences Ltd, Innovent Biologics Inc, Inovio Pharmaceuticals Inc, Intas Pharmaceuticals Ltd, Invectys SA, Inventiva, IO Biotech ApS, Io Therapeutics Inc, Ionis Pharmaceuticals Inc, JHL Biotech Inc, Jiangsu Hansoh Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kadmon Corp LLC, Komipharm International Co Ltd, Kura Oncology Inc, Kyowa Hakko Kirin Co Ltd, Lantern Pharma Inc, Les Laboratoires Servier SAS, Lion Biotechnologies Inc, Loxo Oncology, Inc., Mabion SA, MacroGenics Inc, Mallinckrodt Plc, Mebiopharm Co Ltd, MedImmune LLC, Medisyn Technologies Inc, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Mersana Therapeutics Inc, Microlin Bio, Inc., Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, Molecular Partners AG, MolMed SpA, Morphotek Inc, Multimmune GmbH, Mycenax Biotech Inc, NanoCarrier Co Ltd, Natco Pharma Ltd, Nektar Therapeutics, Nemucore Medical Innovations Inc, NeoPharm Co Ltd, Netris Pharma SAS, Neumedicines Inc, NewLink Genetics Corp, Northwest Biotherapeutics Inc, Novartis AG, NuCana BioMed Ltd, Omnitura Therapeutics Inc, Oncobiologics Inc, Oncogenex Pharmaceuticals Inc, Oncolys BioPharma Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Ono Pharmaceutical Co Ltd, Onxeo SA, Optimum Therapeutics LLC, Oribase Pharma, Oscotec Inc, OSE Immunotherapeutics, Oxford BioTherapeutics Ltd, Paranta Biosciences Ltd, Pfizer Inc, Pharma Mar SA, Philogen SpA, Phosplatin Therapeutics LLC, Pique Therapeutics, Plexxikon Inc, Polaris Pharmaceuticals Inc, ProNAi Therapeutics Inc, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, Puma Biotechnology Inc, Purdue Pharma LP, Qu Biologics Inc, Reata Pharmaceuticals Inc, Recombio SL, Rexahn Pharmaceuticals Inc, Rgenix Inc, Richter Gedeon Nyrt, Samyang Holdings Corp, Sanofi, Sapvax, Scancell Holdings Plc, SciClone Pharmaceuticals Inc, ScinoPharm Taiwan Ltd, Shanghai Fosun Pharmaceutical (Group) Co Ltd, Shanghai Henlius Biotech Co Ltd, Shanghai Pharmaceutical Co Ltd, Shionogi & Co Ltd, Sigma-Tau SpA, SignPath Pharma Inc, Sorrento Therapeutics Inc, Sotio as

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Small-Cell Lung Cancer - Pipeline Review, H2 2016
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
-Non-Small Cell Lung Cancer - Pipeline Review, H1 2016
-Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016
-Small-Cell Lung Cancer - Pipeline Review, H1 2016